2025-07-09


Baheal Pharmaceutical Reappears on the Authoritative Ministry of Industry and Information Technology List, Accelerating the Implementation of Medical Innovation Achievements

  From July 5 to 7, 2025, the 2025 (42nd) National Pharmaceutical Industry Information Annual Conference was held in Beijing. During the conference, a series of rankings such as the "2025 Top 100 Chinese Pharmaceutical Industry Enterprises" were released. Baheal Pharmaceutical (301015.SZ), after being listed in the "China Pharmaceutical Emerging Innovation Forces" list in 2024, was once again honored as the "Best Industrial Enterprise in China's Pharmaceutical R&D Product Line in 2025" due to its outstanding performance in product layout, innovation system, and commercialization platform construction.

Baiyang Pharmaceutical Honored as the Best Industrial Enterprise in China's Pharmaceutical R&D Product Line in 2025

  The selection event for the "Top 100 Chinese Pharmaceutical Industry Enterprises" is organized by the China Pharmaceutical Industry Information Center of the Ministry of Industry and Information Technology. It is one of the most authoritative and influential professional selections in China's pharmaceutical industry. The list is based on national statistical data and comprehensively evaluates enterprises' performance in innovation capability, development potential, market focus, and other dimensions. It is regarded as a wind vane and barometer for the development of the pharmaceutical industry. Among them, the "Best Industrial Enterprise in China's Pharmaceutical R&D Product Line" award, established in 2010, focuses on enterprises' comprehensive performance in systematic product line layout, R&D depth, technological innovation, and industrial transformation efficiency.

  As an innovative brand commercialization platform, Baheal Pharmaceutical has built a full industry chain system covering product development, manufacturing, and commercialization operations. It not only owns a high-end sustained-release formulation R&D and production base (which has passed FDA certification multiple times with "zero defects") and a modern traditional Chinese medicine R&D and production base, but also has established a rich brand matrix in areas such as bone health, liver diseases, metabolic diseases, and tumors, successfully cultivating multiple category-leading brands.

  Based on long-term industrial resource accumulation and the group's innovation resource synergy, Baheal Pharmaceutical has built a differentiated product layout in the fields of oncology and cardiovascular diseases. In oncology, especially in the treatment of brain metastases, the company is promoting a new generation of microtubule inhibitor Utidelone with blood-brain barrier penetration ability, as well as the globally leading brain tumor and lesion radiotherapy device ZAP-X into clinical application; meanwhile, China's first independently innovated nuclear medicine "First-in-Class" innovative drug 99mTc-3PRGD2 has been included in priority review; in the cardiovascular field, the company's operated China's first independently intellectual property fully magnetically suspended artificial heart Cifu VAD has performed excellently in the domestic market, and its clinical trials in the United States have already been carried out in many top international medical institutions; in addition, relying on the scientific research resources of the National Key Laboratory of Cardiovascular Diseases, the company is fully promoting the R&D and transformation of innovative drugs in the cardiovascular field.

  Under the guidance of the innovation transformation strategy, Baheal will rely on the dual drive of internal ecological synergy and external introduction to accelerate the clinical transformation and application of original medical innovation achievements. While continuously enriching the innovation matrix, it will effectively optimize medical scenarios through technological innovation, injecting continuous innovative momentum into the high-quality development of China's pharmaceutical industry.

Related News